PROMOMED Company has received a registration certificate for the drug Tirzetta® in Azerbaijan
30.01.2025
The drug Tirzetta® (Tirzepatide) from PROMOMED It is the first Russian competitor of the well-known and not available in Russia medicinal product Mounjaro.
The drug Tirzetta® is intended for weight loss and treatment of obesity, including in patients with type II diabetes mellitus. The drug was registered by the Ministry of Health of the Russian Federation on January 29, 2025.
The revolutionary effect of the drug consists in a new quality of body weight reduction - a marked decrease in the volume of adipose tissue while carefully preserving the muscular corset and forming a physiologically correct "beautiful" silhouette.
Tirzepatide– the active ingredient of the drug Tirzetta®, is a new class of incretins that activates not one, but two receptors regulating metabolism at once – GLP-1 and GIP. Their combined effect provides greater selectivity of the mechanism of regulation of metabolism, levels of insulin and glucose in the blood and the metabolic rate in specific tissues. As a result, body weight decreases mainly due to increased metabolism of adipose tissue reserves.
Natalia Mokrysheva, Corresponding Member of the Russian Academy of Sciences, Director of the Scientific Research Center of the Russian Federation "NMIC of Endocrinology" of the Ministry of Health of the Russian Federation, Head of the Department of Personalized and Translational Medicine:
"The creation of the first fully domestic tyrzepatide is, of course, a medical, scientific and technological breakthrough. In a very short time, our patients gained access to the best therapeutic solutions for obesity and diabetes that exist in the world. Tirzepatide simultaneously mimics the functions of two physiological regulators by acting on the receptors of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. This is a fundamentally new class aimed at several important components of the key links in the pathophysiological process of obesity and diabetes mellitus, non–communicable pandemics that have swept through modern society. A wide range of therapeutic effects expands the possibilities of its use beyond endocrinology in the future. The prevention of cardiovascular disasters, the treatment of neurodegenerative diseases, kidney dysfunction, and pathologies of the nervous system are the effects of Tirzetta, which will lead to changes in the quality and life expectancy of patients, and these are the drug's prospects that have yet to be revealed."
Tirzetta® will be available as a solution for subcutaneous administration (in dosages: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) in user-friendly intuitive automatic injectors.
The drug will be delivered to pharmacies in the first quarter of this year.
Ilya Bardin-Denisov, General Director of PROMOMED DM LLC, notes: "Today we have taken another important step towards ensuring health and longevity. Tirzetta is the "drug of tomorrow" that can be used today. We continue our work to create innovations not only for tomorrow.
The launch of Tirzetta is a consistent and very important step in the implementation of our strategy, announced during the IPO in July 2024, aimed at defeating the most life–threatening diseases - obesity, diabetes, cancer and superinfections."
The evolution of incretin analogues (physiological regulators of metabolism and appetite) through the consistent creation of drugs based on liraglutide, semaglutide and tirzepatide is a global trend and allows, perhaps for the first time in history, to slow down and even reduce the prevalence of obesity and related diseases at the level of entire states.[1].
The global incretin market is over $44 billion, and is projected to reach $126 billion by 2029.[2].
The Russian market of drugs to combat obesity and diabetes (according to a study by Strategy Partners[3]), in 2025 it will amount to more than 17 billion rubles, compared with 9.5 billion rubles in 2024.
About the Company
PJSC PROMOMED (MOEX: PRMD) (formerly and hereinafter – "PROMOMED", the "Company", and together with its subsidiaries – the "Group") – a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market.
The Company's structure includes its own unique world-class R&D center and a high-tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 330 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts
|
For investors |
For the media |
Statement of limitation of liability
This message and the information contained therein are not:
- an offer to purchase any securities,
- an invitation to make offers for the purchase of any securities,
- as part of such offers or invitations,
- securities advertising in the Russian Federation or other jurisdictions,
- by encouraging or recommending transactions,
- it is also not subject to interpretation as such.
Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.
Neither this announcement nor any part of it should serve as a basis for making any investment decisions.
The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED (hereinafter referred to as the Company) is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the sole source of information when making an investment decision.
Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page. https://e-disclosure.ru/portal/company.aspx?id=38533.
The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). The indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.
The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
Sources
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
